1,900
Participants
Start Date
December 12, 2023
Primary Completion Date
October 31, 2026
Study Completion Date
December 31, 2026
Rapid Diagnostics
Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.
RECRUITING
Taichung Veterans General Hospital, Taichung
NOT_YET_RECRUITING
Sunpasitthiprasong Hospital, Ubon Ratchathani
NOT_YET_RECRUITING
University Malaya Medical Centre, Kuala Lumpur
NOT_YET_RECRUITING
Kaohsiung Medical University Hospital, Kaohsiung City
Collaborators (2)
Pfizer
INDUSTRY
Biomerieux inc
INDUSTRY
National University of Singapore
OTHER